Get started
Author

Olga Oleshko

Observed names: O Oleshko, O. Oleshko, Oleshko, Olga, Olga S. Oleshko
ORCID: 0000-0002-8066-0599
Observed ORCID: 0000-0002-8066-0599
OpenAlex ID: A5089684073
Dehydroabietylamine Ureas and Thioureas as Tyrosyl-DNA Phosphodiesterase 1 Inhibitors That Enhance the Antitumor Effect of Temozolomide on Glioblastoma Cells
2019 · Kseniya Kovaleva, Olga Oleshko, et al. · Journal of Natural Products · 22
Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice
2020 · Nadine Vollack-Hesse, Olga Oleshko, et al. · Blood · 12
PDF
Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study
2022 · Olga Oleshko, Sonja Werwitzke, et al. · Blood Advances · 8
PDF
Vaccine-Induced Thrombocytopenia and Thrombosis (VITT) Antibodies Recognize Neutrophil-Activating Peptide 2 (NAP2) As Well As Platelet Factor 4 (PF4): Mechanistic and Clinical Implications
2021 · Lubica Rauova, Andy Wang, et al. · Blood · 8
1-Hydroxyanthraquinones Containing Aryl Substituents as Potent and Selective Anticancer Agents
2020 · Nafisa S. Sirazhetdinova, Victor A. Savelyev, et al. · Molecules · 6
PDF
Laboratory Monitoring in Patients Receiving Emicizumab
2025 · Jens Müller, Martin Büchsel, et al. · Hämostaseologie · 4
PDF
von Willebrand factor modulates immune complexes and the recall response against factor VIII in a murine hemophilia A model
2023 · Olga Oleshko, Nadine Vollack-Hesse, et al. · Blood Advances · 4
Detection of Anti-drug Antibodies in Patients with Acquired Hemophilia A: Data from the GTH-AHA-EMI Study
2025 · E I Ertekin, A Klingberg, et al. · Hämostaseologie · 1
Effects of secondary factor VIII prophylaxis on joint and bone health in a hemophilia A mouse model
2026 · Lara Monica, Joyce Kimenai, et al. · Haematologica
PDF
Transfer of emicizumab into breast milk in postpartum acquired hemophilia A
2026 · Simon Alexander Krooss, Tim Halling, et al. · Journal of Thrombosis and Haemostasis
PDF
Pharmacodynamic Interaction Between Emicizumab and Coagulation Factor VIII
2026 · Matthias Chill, Emma L. Konarski, et al. · Thrombosis and Haemostasis
Cytokine dynamics following joint injury in hemophilia A mice
2026 · O Oleshko, L Monica, et al. · Hämostaseologie
Characterization of a factor VIII/immunoglobulin heavy chain μ double-knockout mouse model of hemophilia A for long-term exposure to factor VIII proteins
2025 · Lara Monica, Olga Oleshko, et al. · Research and Practice in Thrombosis and Haemostasis
Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis
2025 · Fabius J. Pelzer, Ella I. Ertekin, et al. · Haematologica
PDF
Using FXIa-triggered thrombin generation to assess the risk of breakthrough bleeding in patients receiving emicizumab for acquired Hemophilia A
2025 · Fabius Pelzer, Ella Ertekin, et al. · Blood
PDF
Impact of secondary FVIII prophylaxis on joint bleeding and arthropathy in a Hemophilia A mouse model lacking inhibitor response
2025 · Lara Monica, Joyce Kimenai, et al. · Blood
FXIa-Triggered Thrombin Generation to Predict Breakthrough Bleeding in Acquired Hemophilia A: Data from the GTH-AHA-EMI Study
2025 · S Werwitzke, F Pelzer, et al. · Hämostaseologie
PB0142 FVIII-Containing Immune Complexes Interrupt Platelet Aggregation in an Ex-Vivo Model of Primary Hemostasis
2023 · O. Oleshko, A. Klingberg, et al. · Research and Practice in Thrombosis and Haemostasis
PDF
von Willebrand factor (vWF) significantly modifies the sedimentation profile of FVIII-containing immune complexes (FVIII-IC) based on the type of anti-FVIII antibodies
2021 · O Oleshko, U Curth, et al. · Hämostaseologie
Works count: 20
Citation count: 65
H-index: 5
I10-index: 2
Year
Topic
Type